<DOC>
	<DOCNO>NCT01763398</DOCNO>
	<brief_summary>The domestic standard G-CSF permit use G-CSF ANC ( absolute neutrophil count ) drop 1,000/uL . Therefore impossible inject G-CSF order prevent neutropenia . However , 'the 2006 Update Recommendations Use White Blood Cell Growth Factors : An Evidence-Based Clinical Practice Guideline ( J ClinOncol 2006 ; 24:3187-3205 ) ' 'NCCN Guideline ' revealed precaution , appropriate inject G-CSF non-Hodgkin 's lymphoma patient high-risk factor anticancer treatment CHOP-21 Rituximab number neutrophils decrease . Thus , intend analyze risk factor febrile neutropenia high-risk group non-Hodgkin 's lymphoma patient neutropenic fever receive CHOP-like regimen primary G-CSF prophylactic therapy every three week . ( The definition neutropenic fever fever 38.3 degree C continuous fever lasting longer 1 hour 38 degree C number neutrophil ≤ 500/uL neutrophil ≤ 1,000/uL case expect decline ≤ 500/uL within 48 hour . )</brief_summary>
	<brief_title>Analysis Risk Factors Neutropenic Fever High Risk NHL Patients Developing Febrile Neutropenia Who Received 3-weekly CHOP-like Chemotherapy With Primary G-CSF Prophylaxis ; Prospective Multicenter Observation Study</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Histologically diagnose nonHodgkin 's lymphoma patient treat CHOPregimen R ( Rituximab ) CHOP regimen 21±5 day interval Age &gt; = 20 year old The patient least one follow risk factor neutropenic fever initiation anticancer treatment 1 . Age &gt; = 65 year old 2 . Progressed stage disease ( Ann Arbor stage III ) 3 . History previous anticancer treatment 4 . History previous radiotherapy ( Including bone region include bone marrow ) 5 . Bone marrow involvement 6 . Comorbid neutropenia ( neutrophils &lt; 1,500/uL ) initiation anticancer treatment 7 . Comorbid anemia ( hemoglobin &lt; 12.0 g/dL ) initiation anticancer treatment 8 . Evidence activate inflammation 9 . Existence open wind 10 . Poor health state ( ECOG 2 ) 11 . Poor nutritional state ( Serum albumin &lt; 3.5 g/dL ) 12 . Kidney disease renal insufficiency 13 . Liver disease ( chronic hepatitis cirrhosis ) hepatic insufficiency 14 . Chronic Obstructive Pulmonary Disease ( COPD ) 15 . Cardiovascular disease 16 . Diabetes mellitus Increased cardiac output 50 % baseline without clinically significant abnormal finding MUGA echocardiography life expectancy &gt; =6 month Amenorrhea le 1 year ( less 1 year menopause ) premenopausal female negative response serum urine pregnancy test initiation treatment Voluntary participant write consent agreement study The patient treat anticancer treatment except CHOP regimen R ( Rituximab ) CHOP regimen 21 day interval Pregnant breast feed woman , fertile woman without appropriate contraception Patients hypersensitivity study drug Patients treat study medication cotreatment anticancer chemotherapy , hormone therapy , immunotherapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>